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Klein et al.1 present a timely analysis on the cost-effectiveness of maintenancepemetrexed (Pem) in the treatment of advanced (stage IIIB/IV) non-small cell lung
cancer (NSCLC), a relatively young treatment paradigm, in this issue of the Journal of
Thoracic Oncology. After all, recent debate over health care reform has shed a new light
on rising medical costs and their consequences for national economic health. This concern
is particularly germane to cancer care for which the development of expensive novel
therapeutics,2,3 limited cost controls,4 and increases in the percentage of patients receiving
all types of therapy are contributing to increased health care expenditures.5
In this study, the primary analysis used the results of an international phase III trial
published in 2009, which demonstrated improved progression-free and overall survival in
patients receiving Pem over best supportive care alone in the maintenance setting,
primarily accounted for by patients with nonsquamous histologies.6 The authors applied
these results, data on adverse events, and cost estimates from a claims database as inputs
to a semi-Markov model (a type of computer-based simulation of disease trajectory) to
estimate life-years gained (LYGs) and the incremental cost-effectiveness ratio (ICER) of
Pem maintenance therapy compared with best supportive care from the perspective of the
health care payer. As secondary analyses, the authors compare Pem maintenance with the
estimated ICERs for maintenance erlotinib or bevacizumab from other analyses.
The authors used the recommended methods for cost-effectiveness research,7
including the use of intention-to-treat outcomes, applying a discount rate, providing
sensitivity analyses to account for uncertainty, and using ICERs. Yet, in this study, the
authors opted to measure outcomes in LYGs as opposed to the preferred quality-adjusted
life-years; using the former measure will tend to make treatments of patients with
advanced cancer more cost-effective than they actually are.
This study evaluated subsets based on histology (squamous versus nonsquamous),
a prespecified analysis in the original study although one for which no stratification was
performed. In the absence of clinical trials directly comparing Pem to either erlotinib or
bevacizumab in the maintenance setting, the authors instead relied on extrapolating data
from other phase III trials, limiting the quality of the model assumptions used for the
secondary analyses and making these comparisons less convincing. The key result then
was the finding of the primary analysis that demonstrated an ICER of $122,371 per
life-year gained in nonsquamous histology NSCLC. When all NSCLC histologies were
included, the ICER increased to $205,597.
So how do we use this information? To place their results into context, the authors
cite the analysis by Braithwaite et al. that suggested a range for acceptable cost between
$95,000 and $264,000 per LYG based on estimates of advances in health care and medical
costs relative to 1950 and the benefits of insurance against the costs of noninsurance.8
Others have proposed the cost-effectiveness of renal dialysis ($120,090 per quality-
adjusted life-year) as a benchmark.3 Regardless, these different ranges provide only
theoretical guidance in the United States, where cost effectiveness analyses have no
meaningful policy ramifications. The Food and Drug Administration has already approved
Pem for maintenance therapy, but approval does not require or imply an assessment of
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cost-effectiveness. In addition, the Centers for Medicare and
Medicaid Services remain restricted in its ability to curtail
pharmaceutical costs.4
To some degree, these data could potentially be used by
individual physicians to make treatment decisions, as sug-
gested by a recent survey of American Society of Clinical
Oncology member oncologists,9 but it is not altogether clear
how. Although 70% of survey respondents would not con-
sider this therapy cost-effective based on their reported per-
sonal thresholds (no more than $100,000 per LYG), only 42%
felt “well-prepared to interpret and use cost-effectiveness
information in [their] treatment decisions.” Matters are fur-
ther complicated when the priorities of the general population
are considered. In a 2006 cross-sectional survey conducted by
the National Opinion Research Center of the University of
Chicago, 73.5% of the respondents thought that the nation
was spending too little on improving and protecting the
nation’s health.10 In the public eye, expectations of our health
care system seem to remain uncoupled to costs.
Given the estimate of cost-effectiveness in the study, it
may come as a surprise for readers that the United Kingdom’s
National Institute for Health and Clinical Excellence (NICE)
approved Pem as maintenance therapy for advanced nonsqua-
mous NSCLC. Nevertheless, this approval was based on an
estimated ICER of £47,000 (approximately US $73,000) for
Pem in the same clinical setting.11 Why was Pem nearly twice
as cost-effective in the NICE analysis as it appears to be in
the one from Klein et al.? The answer is simple—the cost of
the drug. The model submitted to NICE assumed a drug cost
of £800 (approximately US $1250) per 500 mg for patients in
the United Kingdom, whereas this study assumes a drug cost
twice as high for patients in the United States (Table 1). Same
drug, same indication, and in fact the same underlying trial
data were used to generate the estimates.
That the United Kingdom is able to obtain Pem for a
lower cost than it is sold for in the United States is likely a
reflection of their strong regulatory approach to coverage and
reimbursement. If the drug were not cost-effective, then it
would not be used. So, to achieve cost-effectiveness, the
manufacturer lowers the price. In the United States, the fact
that Pem provides clear clinical benefit in the maintenance
setting is all that is needed to ensure its use. Although we
want patients to have access to such efficacious therapies, can
we really expect a fundamentally cost-insensitive approach to
be sustainable? Someday, perhaps, we will have a clear
policy in the United States about cost-effectiveness, so that
manufacturers adjust their pricing to meet prespecified
thresholds. But today, our efforts to generate more and more
precise estimates of cost-effectiveness analogize to the pro-
verbial dog chasing a car down the street. He has no plan for
what he will do when he catches it.
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TABLE 1. Comparison of Drug Costs and ICER Estimates
Based on Cost-Effectiveness Analyses Presented in NICE
Approval Analysis and in Current Study
NICE Estimates
for UKa
Current Study’s
Estimates for US
Cost of pemetrexed per
500-mg vial
$1248 (£800) $2408
ICER for nonsquamous
histology
$73,323 (£47,000) $122,371
a British pound to US dollar exchange rate calculated using 2010 first quarter
average (1 USD  0.641 GBP).
NICE, National Institute for Health and Clinical Excellence; ICER, incremental
cost-effectiveness ratio.
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